July 26, 2021Open Access
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Key Points
Key points are not available for this paper at this time.
Abstract
In this first direct comparison of less versus more selective Bruton's tyrosine kinase inhibitors in CLL, acalabrutinib demonstrated noninferior PFS with fewer cardiovascular adverse events.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Cite this study
Byrd et al. (Mon,) studied this question.
synapsesocial.com/papers/69df6e4258b92af24d7a18ea — DOI: https://doi.org/10.1200/jco.21.01210
Authors
John C. Byrd
Northwestern University
P
Peter Hillmen
Leeds Teaching Hospitals NHS Trust
P
Paolo Ghia
Vita-Salute San Raffaele University
Journals
Journal of Clinical Oncology
Actions
Institutions
Cornell University
University of Pennsylvania
The Ohio State University
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...